Abstract:Objective:To analyze the clinical features of type 2 diabetic patients with insulin autoimmune syndrome after treatment with exogenous insulin.Methods:A total of 106 patients with type 2 diabetes diagnosed with exogenous insulin-related insulin autoimmune syndrome (EIAS) were included from September 2017 to March 2019 in the Department of Endocrinology, Zhongshan Hospital, Fudan University. The clinical data, physical examination, and laboratory examination results of patients were collected.Results:Of the 106 patients, 84 (79.24%) used premixed human insulin or premixed insulin analogs, and 18 patients (16.98%) presented recurrent hypoglycemia. The arginine stimulation test showed that the median value of the baseline insulin was 73.40 (23.07-146.75) μU/ml, and the median ratio of 4 minute insulin to 0 minute insulin was 1.27 (1.03-1.85), with the mean of the ratio 1.72±1.47. The ratio of baseline insulin (μU/ml) to C-peptide (ng/ml) was 44.60 (14.92-87.93), with an average of 81.92±130.93. Taking the two-fold upper limit of fasting insulin reference value (49.8 μU/ml) as the cut-off point, the subjects were divided into insulin accumulation group (baseline insulin≥49.8 μU/ml) and insulin non-accumulation group (baseline insulin <49.8 μU/ml). Among the 66 patients in the insulin accumulation group, 14 patients had hypoglycemia (21.21%) and 4 patients in the insulin non-accumulation group presented hypoglycemia (10%). The ratio of 4 minute insulin to baseline insulin, ratio of baseline insulin to C-peptide, blood glucose level standard deviation (SDBG) and maximum blood glucose fluctuation amplitude (LAGE) in the insulin accumulation group were significantly higher than those in the insulin non-accumulation group (all P<0.05). Among 66 patients in the insulin accumulation group, 36 patients changed the type of insulin preparafion (insulin treatment group), 30 patients were changed from insulin to oral hypoglycemic agents (oral medication group). After treatment, both SDBG and LAGE in the two groups were significantly lower than before treatment ( P<0.05). Conclusions:With the aggravation of exogenous insulin accumulation, the fluctuation of blood glucose and the proportion of hypoglycemia were significantly increased. There was a characteristic change in islet function in patients with insulin autoimmune syndrome. After arginine stimulation, there was no significant peak of insulin secretion, showing a " high-level" curve. The baseline insulin/C-peptide ratio was significantly increased. The prognosis of EIAS patients is good after timely diagnosis and adjustment of treatment.

Association between glucose-lowering drugs and circulating insulin antibodies induced by exogenous insulin therapy in patients with type 2 diabetes

Association between glucose-lowering drugs and circulating insulin antibodies induced by insulin therapy in patients with type 2 diabetes

[A Clinical Analysis of Insulin Antibody in Type 2 Diabetic Patients].

1093-P: the Prevalence and Clinical Characteristics of Insulin Antibody Formation in Patients with Type 2 Diabetes Treated with Insulin

Study on relationship between serum insulin/C peptide ratio and insulin antibody in type 2 diabetic patients treated with exogenous insulin

Analysis on clinical features of 106 type 2 diabetic patients complicated with insulin autoimmune syndrome

Recurrent hypoglycemic coma and diabetic ketoacidosis caused by insulin antibody. A rare case of type 1 diabetes mellitus

Association Between Serum IL-18 Level and Cytokine in Type 1 Diabetes Mellitus in Children

The Clinical Efficacy of ICA and GAD-Ab in Diabetes Mellitus

The Clinical Implications of Fasting Serum Insulin Levels in Patients with Insulin-Treated Type 2 Diabetes: a Cross-Sectional Survey

Characteristics of OGTT and Correlation Between the Insulin to C-Peptide Molar Ratio, HOMA-IR, and Insulin Antibodies in T2DM Patients

When discordant insulin and C-peptide levels lead to a medical diagnosis in a patient with transient hypoglycemia: Varying degrees of interference of insulin-antibody complexes on three insulin immunoassays

Relationship Between Serum Glutamic Acid Decarboxylase Antibody Titer and the First-Phase Insulin Release in Newly-Diagnosed Type 2 Diabetic Patients

Distribution of Autoantibodies to Insulinoma‐associated Antigen‐2 and Zinc Transporter 8 in Type 1 Diabetes and Latent Autoimmune Diabetes: A Nationwide, Multicentre, Cross‐sectional Study

Diagnosis and treatment of anti-insulin antibody-mediated labile glycaemia in insulin-treated diabetes

Gliclazide - Induced Insulin Autoimmune Syndrome: A Rare Case Report and Review on Literature.

Analysis of clinical features of type 1 diabetes patients with positive autoantibodies from different pancreatic island

Insulin antibodies in patients with type 2 diabetic receiving recombinant human insulin injection: A report of 12 cases.

The association of islet autoantibodies with the neural retinal thickness and microcirculation in type 1 diabetes mellitus with no clinical evidence of diabetic retinopathy

Diagnosis and therapy experience of Insulin Autoimmune Syndrome in a single Chinese center v1

Exogenous insulin autoimmune syndrome: A case report and review of literature